natgillin/translations-raw huggingface dataset:
Take the soluble tablets as a single daily dose with a meal to increase the absorption, and at the same time each day, preferably in the morning.
19 hrane, ki poveča absorbcijo, vsak dan ob istem času, najbolje zjutraj.
19 BH4 deficiency The usual starting dose of Kuvan in adult and paediatric patients with BH4 deficiency is 2 to 5 mg for each kg of body weight.
Pomanjkanje BH4 Običajni začetni odmerek zdravila Kuvan pri odraslih in pediatričnih bolnikih s pomanjkanjem BH4 je 2 do 5 mg na vsak kg telesne mase.
Take the soluble tablets as a single daily dose, with a meal to increase the absorption, and at the same time each day, preferably in the morning.
Tablete za peroralno raztopino vzemite v enkratnem dnevnem odmerku ob obroku hrane, ki poveča absorbcijo, vsak dan ob istem času, najbolje zjutraj.
The table below is an example of how an appropriate dose is calculated:
Spodnja tabela podaja primer izračuna ustreznega odmerka:
(Kuvan dose 10 mg/ kg)
(odmerek zdravila Kuvan 10 mg/ kg)
(Kuvan dose 20 mg/ kg)
(odmerek zdravila Kuvan 20 mg/ kg)
Adults Place the tablets in a glass or cup (120 to 240 ml) of water and stir until dissolved.
Odrasli Tablete dajte v kozarec ali skodelico z vodo (120 do 240 ml) in mešajte dokler se ne raztopijo.
Paediatric patients The prescribed number of tablets should be placed in a glass or cup (up to 120 ml) of water and stir until dissolved.
Pediatrični bolniki Predpisano število tablet je treba dati v kozarec ali skodelico z vodo (do 120 ml) in mešati dokler se ne raztopijo.
For doses below 100 mg, one tablet should be dissolved in 100 ml of water.
Za odmerke manjše od 100 mg je potrebno raztopiti eno tableto v 100 ml vode.
Your doctor will tell you to administer only a certain volume of the solution corresponding to the appropriate dose.
Vaš zdravnik vam bo povedal, da otroku date le določeno količino raztopine, ki ustreza predpisanemu odmerku.
An accurate measuring device with suitable graduations should be used for this purpose.
Za ta namen je potrebno uporabiti natančno merilno pripravo z ustrezno skalo.
It may take a few minutes for the tablets to dissolve.
Lahko traja nekaj minut, preden se tablete raztopijo.
Small particles may be visible in the solution, but they will not affect the effectiveness of the medicine.
V raztopini so lahko vidni majhni delci, ki pa ne vplivajo na učinkovitost zdravila.
Drink the dissolved preparation of Kuvan with a meal, at the same time each day, preferably in the morning within 15 to 20 minutes of its preparation.
Raztopino zdravila Kuvan popijte ob obroku, vsak dan ob istem času, najbolje zjutraj, v 15 do 20 minutah po pripravi.
Make sure you do not swallow the desiccant capsule contained in the bottle.
Pazite, da ne zaužijete kapsule s sušilnim sredstvom, ki se nahaja v plastenki.
If you take more Kuvan than you should If you take more Kuvan than prescribed, you may experience side effects that could include headache and dizziness.
Če ste vzeli večji odmerek zdravila Kuvan, kot bi smeli Če vzamete večji odmerek zdravila Kuvan od predpisanega, se pri vas lahko pojavijo neželeni učinki, ki lahko vključujejo glavobol in omotico.
You should immediately contact your doctor or pharmacist if you take more Kuvan than prescribed.
Če ste vzeli večji odmerek zdravila Kuvan od predpisanega, se takoj posvetujte z zdravnikom ali s farmacevtom.
If you forget to take Kuvan Do not take a double dose to make up for a forgotten dose.
Če ste pozabili vzeti zdravilo Kuvan Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
If you stop taking Kuvan Do not stop taking Kuvan without prior discussion with your doctor, as phenylalanine levels in the blood may increase.
Če ste prenehali jemati zdravilo Kuvan Z jemanjem zdravila Kuvan ne smete prenehati, ne da bi se pred tem posvetovali s svojim zdravnikom, ker se ravni fenilalanina v krvi lahko zvišajo.
Like all medicines, Kuvan can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Kuvan neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Frequencies of side effects are defined as:
Pogostnost neželenih učinkov je opredeljena kot sledi:
- very common: affects more than 1 user in 10
- zelo pogosti: pojavijo se pri več kot 1 od 10 uporabnikov.
- common: affects 1 to 10 users in 100
- pogosti: pojavijo se pri 1 do 10 uporabnikih od 100.
- uncommon: affects 1 to 10 users in 1,000
- občasni: pojavijo se pri 1 do 10 uporabnikih od 1. 000.
- rare: affects 1 to 10 users in 10,000
- redki: pojavijo se pri 1 do 10 uporabnikih od 10. 000.
- very rare: affects less than 1 user in 10,000
- zelo redki: pojavijo se pri manj kot 1 uporabniku od 10. 000.
Very common side effects: headache and runny nose.
Zelo pogosta neželena učinka: glavobol in izcedek iz nosu.
Common side effects: sore throat, nasal congestion or stuffy nose, cough, diarrhoea, vomiting, stomach ache and too low levels of phenylalanine in blood tests.
Pogosti neželeni učinki: vneto grlo, zamašen nos, kašelj, driska, bruhanje, bolečine v trebuhu in prenizka raven fenilalanina pri preiskavah krvi.
HOW TO STORE KUVAN
SHRANJEVANJE ZDRAVILA KUVAN
Do not use Kuvan after the expiry date which is stated on the bottle and the carton after “ EXP”.
Zdravila Kuvan ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake "Uporabno do:".
What Kuvan contains
Kaj vsebuje zdravilo Kuvan
Each tablet contains 100 mg of sapropterin
Ena tableta vsebuje 100 mg sapropterinijevega
dihydrochloride (equivalent to 77 mg of sapropterin).
diklorida (kar ustreza 77 mg sapropterina).
- The other ingredients are mannitol (E421), calcium hydrogen phosphate anhydrous,
- Pomožne snovi so manitol (E421), kalcijev hidrogenfosfat, brezvodni, krospovidon tip A,
crospovidone type A, ascorbic acid (E300), sodium stearyl fumarate, and riboflavin (E101).
askorbinska kislina (E300), natrijev stearilfumarat in riboflavin (E101).
Kuvan is supplied as soluble tablets.
Zdravilo Kuvan je na voljo v obliki tablet za peroralno raztopino.
The soluble tablets are off-white to light yellow and have “ 177 ” imprinted on one face.
Tablete za peroralno raztopino so belkaste do svetlo rumene barve, z napisom "177" na eni strani.
It may be available in bottles with child-resistant closure of 30, 120 or 240 soluble tablets.
Zdravilo Kuvan je na voljo v plastenkah z za otroke varno zaporko po 30, 120 ali 240 tablet za peroralno raztopino.
21 Marketing Authorisation Holder and Manufacturer
21 Imetnik dovoljenja za promet in izdelovalec
23 This leaflet was last approved in
23 Navodilo je bilo odobreno
EMEA/ 522632/ 2008
EMEA/ 605943/ 2008 Error!
On 25 September 2008, UCB Pharma S. A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Lacosamide Pain UCB Pharma, for the treatment of diabetic neuropathic pain in adults.
Družba UCB Pharma S. A. je dne 25. septembra 2008 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za dovoljenje za promet z zdravilom Lacosamide Pain UCB Pharma, namenjenim zdravljenju boleče diabetične nevropatije pri odraslih.
Pain was measured by the patients on an 11-point scale.
Bolniki so bolečino merili s pomočjo 11- stopenjske lestvice.
Based on the review of the data and the company’ s response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Lacosamide Pain UCB Pharma could not have been approved for the treatment of diabetic neuropathic pain in adults.
Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je zastavil CHMP v času umika vloge, je imel Odbor zadržke in je začasno menil, da zdravila Lacosamide Pain UCB Pharma ni mogoče odobriti za zdravljenje boleče diabetične nevropatije pri odraslih.
Therefore, at the time of the withdrawal, the CHMP’ s view was that a benefit of Lacosamide Pain UCB Pharma had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
CHMP je zato v času umika menil, da koristi zdravila Lacosamide Pain UCB Pharma niso bile zadostno dokazane in da ne odtehtajo znanih tveganj.
Lantus is a clear solution for injection containing the active substance insulin glargine.
Zdravilo Lantus je bistra raztopina za injiciranje, ki vsebuje zdravilno u inkovino insulin glargin.
It is supplied in vials, cartridges, cartridges for OptiClik, or pre-filled disposable pens (OptiSet and SoloStar).
Na voljo je v vialah, injekcijskih vložkih, injekcijskih vložkih za OptiClik ali predhodno napolnjenih injekcijskih peresnikih za enkratno uporabo (OptiSet in SoloStar).
Lantus is used to treat adults, adolescents and children aged six years or older with diabetes mellitus, when they need insulin.
Zdravilo Lantus se uporablja za zdravljenje odraslih, mladostnikov in otrok, starih šest let ali ve, ki imajo sladkorno bolezen in potrebujejo insulin.
Lantus is given by injection under the skin in the abdominal wall (tummy), the thigh, or the deltoid region (shoulder).
Zdravilo Lantus se daje z injiciranjem pod kožo v trebušno steno (trebuh), stegno ali deltoidno mišico (ramo).
The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the insulin work less well than expected.
Mesto injiciranja je treba pri vsaki injekciji menjati, da se prepre ijo spremembe na koži (kot je odebelitev), zaradi esar bi lahko insulin deloval slabše od pri akovanega.
The patient ’ s blood glucose (sugar) should be regularly tested to find the lowest effective dose.
Raven glukoze (sladkorja) v krvi bolnika je treba redno preverjati, da dolo imo najmanjši u inkovit odmerek.
Lantus is given once daily at any time during the day provided that it is the same time each day.
Zdravilo Lantus se daje enkrat dnevno ob kateri koli uri, pod pogojem, da se daje vedno ob isti uri.
This should be in the evening when used in children.
Kadar se uporablja pri otrocih, se mora dajati zve er.
Lantus can also be given together with anti-diabetes medicines taken by mouth in patients who have non-insulin-dependent diabetes (type 2 diabetes).
Pri bolnikih, ki imajo od insulina neodvisno sladkorno bolezen (sladkorno bolezen tipa II), lahko zdravilo Lantus dajemo skupaj s peroralnimi zdravili za sladkorno bolezen.
Diabetes is a disease in which the body does not produce enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Sladkorna bolezen je bolezen, pri kateri telo ne proizvaja dovolj insulina za vzdrževanje primerne koncentracije glukoze v krvi ali pri kateri telo ne more insulina u inkovito uporabljati.
Lantus is a replacement insulin that is very similar to the insulin made by the pancreas.
Zdravilo Lantus je nadomestni insulin, ki je zelo podoben insulinu, ki ga proizvaja trebušna slinavka.
It is made by a bacterium that has received a gene (DNA), which makes it able to produce insulin glargine.
Zdravilno u inkovino v zdravilu Lantus, insulin glargin, proizvajajo z metodo, znano kot „ tehnologija rekombinantne DNK “, pri kateri bakterija prejme gen (DNK), s katerim lahko tvori insulin glargin.
Insulin glargine is very slightly different from human insulin.
Insulin glargin se zelo malo razlikuje od humanega insulina.
The change means that it is absorbed more slowly and regularly by the body after an injection, and that it has a long duration of action.
Razlika se odraža v po asnejši in rednejši absorpciji v telo po injiciranju ter v daljšem trajanju delovanja.
The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood.
Nadomestni insulin deluje na enak na in kot naravno proizveden insulin in omogo a, da lahko glukoza vstopi iz krvi v celico.
By controlling blood glucose levels, the symptoms and complications of diabetes are reduced.
Z nadzorovanjem sladkorja v krvi se zmanjšajo simptomi in zapleti, povezani s sladkorno boleznijo.
Reproduction is authorised provided the source is acknowledged How has Lantus been studied?
Kako je bilo zdravilo Lantus raziskano?
Lantus was originally studied in 10 studies, in both type 1 and type 2 diabetes.
Zdravilo Lantus so prvotno preu ili v 10 študijah, pri sladkorni bolezni tipa 1 in tudi sladkorni bolezni tipa 2.
A total of 2,106 patients received Lantus in all trials combined.
Zdravilo Lantus je v vseh preskušanjih prejelo skupno 2106 bolnikov.
The main studies compared Lantus given once a day at bedtime with human insulin NPH (an intermediate-acting insulin) given once or twice a day.
V glavnih študijah so primerjali prejemanje zdravila Lantus enkrat dnevno pred spanjem in prejemanje humanega insulina NPH (insulina s srednjedolgim delovanjem) enkrat ali dvakrat dnevno.
Injections of fast-acting insulin were also used at mealtimes.
V asu obrokov so uporabili tudi injekcije hitro delujo ega insulina.
In one study, patients with type 2 diabetes also received anti-diabetes medicines by mouth.
V eni študiji so bolniki s sladkorno boleznijo tipa II prejeli tudi peroralna zdravila za sladkorno bolezen.
Further studies were carried out to compare Lantus and human insulin NPH in children and adolescents aged between five and 18 years, 200 of whom received Lantus.
Izvedene so bile dodatne študije, v katerih so zdravilo Lantus primerjali s humanim insulinom NPH pri otrocih in mladostnikih, starih med pet in 18 let, od katerih jih je 200 prejelo zdravilo Lantus.
Studies were also carried out in nearly 1,400 adult patients with type 1 or type 2 diabetes to measure the effectiveness of Lantus injected at any time during the day, compared with an evening injection.
Študije so bile izvedene tudi na skoraj 1400 odraslih bolnikih s sladkorno boleznijo tipa 1 ali 2, da bi izmerili u inkovitost zdravila Lantus, injiciranega ob katerem koli asu dneva, v primerjavi z injiciranjem pred spanjem.
All of the studies measured the level of ‘ fasting’ blood glucose (measured after not eating for at least eight hours) or of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
V vseh študijah so merili raven glukoze v krvi na teš e (izmerjeno vsaj osem ur po zadnjem obroku) ali snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako u inkovito je raven glukoze v krvi nadzorovana.
Lantus led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with human insulin.
Zdravilo Lantus je povzro ilo znižanje ravni HbA1c, kar kaže, da so bile ravni glukoze v krvi uravnane na podobno raven kot pri humanem insulinu.
Lantus was effective for both type 1 and type 2 diabetes.
Zdravilo Lantus je bilo u inkovito za sladkorno bolezen tipa I in tudi za sladkorno bolezen tipa II.
However, there were too few children aged below six years to determine the medicine ’ s effectiveness in this group.
Vendar pa je bilo premalo otrok, mlajših od šest let, da bi lahko dolo ili u inkovitost zdravila v tej skupini.
The effectiveness of Lantus was seen regardless of the time of the injection.
Opazili so, da je zdravilo Lantus u inkovito ne glede na uro injiciranja.
The most common side effect with Lantus (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels).
Najpogostejši neželeni u inek zdravila Lantus (opažen pri ve kot 1 bolniku izmed 10) je hipoglikemija (nizka raven glukoze v krvi).
Reactions at the site of the injection (redness, pain, itching and swelling) have been seen more often in children than in adults.
Reakcije na mestu injiciranja (rde ina, bole ine, srbe ica in otekanje) so bile pogosteje opažene pri otrocih kot odraslih.
For the full list of all side effects reported with Lantus, see the Package Leaflet.
Za celoten seznam neželenih u inkov, o katerih so poro ali pri uporabi zdravila Lantus, glejte navodilo za uporabo.
Lantus should not be used in people who may be hypersensitive (allergic) to insulin glargine or to any of the other ingredients.
Zdravila Lantus ne smejo uporabljati osebe, ki so preob utljive za (alergi ne na) insulin glargin ali katero koli drugo sestavino zdravila.
Lantus doses might also need to be adjusted when given with some other medicines that may have an effect on blood glucose levels.
Odmerke zdravila Lantus bo morda treba prilagoditi, e se jemlje so asno s katerim od drugih zdravil, ki vplivajo na raven sladkorja v krvi.
The Committee for Medicinal Products for Human Use (CHMP) decided that Lantus’ s benefits are greater than its risks for the treatment of adults, adolescents and children of six years or above with diabetes mellitus, where treatment with insulin is required.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaklju il, da so koristi zdravila Lantus za zdravljenje sladkorne bolezni pri odraslih, mladostnikih in otrocih, starejših od šest let, pri katerih je potrebno zdravljenje z insulinom, ve je od z njim povezanih tveganj.
The Committee recommended that Lantus be given marketing authorisation.
Odbor je priporo il, da se za zdravilo Lantus odobri dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union for Lantus to Sanofi-Aventis Deutschland GmbH on 9 June 2000.
Evropska komisija je dovoljenje za promet z zdravilom Lantus, veljavno po vsej Evropski uniji, odobrila družbi Sanofi- Aventis Deutschland GmbH dne 9. junija 2000.
The marketing authorisation was renewed on 9 June 2005.
Dovoljenje za promet z zdravilom je bilo podaljšano dne 9. junija 2005.
The full EPAR for Lantus is available here.
Celotno evropsko javno poro ilo o oceni zdravila (EPAR) za zdravilo Lantus je na voljo tukaj.
This summary was last updated in 04-2008
Povzetek je bil nazadnje posodobljen 04- 2008.
Pharmaceutical Form
farmacevtska oblika pot uporabe
Route of Administration
ovojnina
Content
100 enot/ ml
Package size
za subkutano
Subcutaneous use
raztopina za uporabo injiciranje v viali
Solution for injection in a vial
raztopina za za subkutano
Subcutaneous use
EU/ 1/ 00/ 134/ 002
Subcutaneous use
EU/ 1/ 00/ 134/ 003
Subcutaneous use
EU/ 1/ 00/ 134/ 004
Solution for injection in a cartridge
za subkutano
Subcutaneous use
raztopina za uporabo injiciranje v vložku
Solution for injection in a cartridge
raztopina za za subkutano
Subcutaneous use
EU/ 1/ 00/ 134/ 006
cartridge (glass)
injiciranje v vložku uporabo
Subcutaneous use
EU/ 1/ 00/ 134/ 007
Solution for injection
za subkutano
Subcutaneous use
raztopina za uporabo
cartridge (glass) in a pre- filled pen (OptiSet)
vložek (steklen) v napolnjenem
Subcutaneous use
injiciranje uporabo raztopina za za subkutano
cartridge (glass) in a pre- filled pen (OptiSet)
vložek (steklen) v napolnjenem injekcijskem peresniku (OptiSet)
Subcutaneous use
injiciranje uporabo za subkutano
Solution for injection
injiciranje raztopina za
Subcutaneous use
uporabo za subkutano
Solution for injection in a cartridge
raztopina za injiciranje v vložku
Solution for injection in a cartridge
raztopina za
Solution for injection in a cartridge
injiciranje v vložku
Subcutaneous use
raztopina za
cartridge (glass) in a pre- filled pen (SoloStar)
vložek (steklen) v napolnjenem
cartridge (glass) in a pre- filled pen (SoloStar)
injekcijskem peresniku (SoloStar)
EU/ 1/ 00/ 134/ 034
peresniki
EU/ 1/ 00/ 134/ 035
5 napolnjenih
100 Units/ ml
injiciranje
8 pre-filled pens
injekcijskih peresnikov
EU/ 1/ 00/ 134/ 036
EU/ 1/ 00/ 134/ 034 EU/ 1/ 00/ 134/ 035
100 Units/ ml
100 enot/ ml 100 enot/ ml
Subcutaneous use
za subkutano uporabo za subkutano uporabo
cartridge (glass) in a pre- filled pen (SoloStar)
vložek (steklen) v napolnjenem injekcijskem peresniku (SoloStar) vložek (steklen) v napolnjenem injekcijskem peresniku (SoloStar)
3 ml
3 ml 3 ml
9 pre-filled pens
6 napolnjenih injekcijskih peresnikov 8 napolnjenih injekcijskih peresnikov
EU/ 1/ 00/ 134/ 037
2/ 3 EU/ 1/ 00/ 134/ 036 EU/ 1/ 00/ 134/ 037
10 pre-filled pens
9 napolnjenih injekcijskih peresnikov 10 napolnjenih injekcijskih peresnikov
Lantus 100 Units/ ml solution for injection in a vial
Lantus 100 enot/ ml raztopina za injiciranje v viali
Each ml contains 100 Units insulin glargine (equivalent to 3.64 mg).
En mililiter vsebuje 100 enot insulina glargin (kar ustreza 3, 64 mg).
Each vial contains 5 ml of solution for injection, equivalent to 500 Units, or 10 ml of solution for injection, equivalent to 1000 Units.
Vsaka viala vsebuje 5 ml raztopine za injiciranje, kar ustreza 500 enotam, ali 10 ml raztopine za injiciranje, kar ustreza 1. 000 enotam.
Insulin glargine is produced by recombinant DNA technology in Escherichia coli.
Insulin glargin je pridobljen s tehnologijo rekombinantne DNA iz bakterij Escherichia coli.
For the treatment of adults, adolescents and children of 6 years or above with diabetes mellitus, where treatment with insulin is required.
Zdravljenje odraslih, mladostnikov in otrok, starih 6 let ali več, ki imajo diabetes mellitus in potrebujejo zdravljenje z insulinom.
These units are exclusive to Lantus and are not the same as IU or the units used to express the potency of other insulin analogues.
Te enote veljajo izključno za zdravilo Lantus in niso enake mednarodnim enotam (i. e.) ali enotam, ki se uporabljajo za izražanje jakosti drugih insulinskih analogov.
Lantus contains insulin glargine an insulin analogue with a prolonged duration of action.
Zdravilo Lantus vsebuje insulin glargin, insulinski analog s podaljšanim delovanjem.
It should be administered once daily at any time but at the same time each day.
Aplicirati ga je treba enkrat na dan, in sicer kadarkoli, vendar vsak dan ob istem času.
The dosage and timing of dose of Lantus should be individually adjusted.
Odmerjanje in čas apliciranja zdravila Lantus morata biti prilagojena individualno.
In children, efficacy and safety of Lantus have only been demonstrated when given in the evening.
Pri otrocih sta učinkovitost in varnost zdravila Lantus dokazani samo pri uporabi zvečer.
Due to limited experience, the efficacy and safety of Lantus have not been demonstrated in children below the age of 6 years.
Zaradi omejenih izkušenj učinkovitost in varnost zdravila Lantus nista dokazani pri otrocih do 6. leta starosti.
Transition from other insulins to Lantus
Prehod z drugih insulinov na zdravilo Lantus
When changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with Lantus, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast- acting insulin analogues or the dose of oral antidiabetic agents).
Pri prehodu s srednjedolgo - ali dolgodelujočega insulina na zdravljenje z zdravilom Lantus utegneta biti potrebna sprememba odmerka bazalnega insulina in prilagoditev sočasnega antidiabetičnega zdravljenja (odmerek in časovni razpored dodatnih običajnih insulinov ali hitrodelujočih insulinskih analogov oz. odmerek peroralnih antidiabetikov).
2 To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with Lantus should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.
2 Bolniki, ki z insulina NPH dvakrat na dan preidejo na zdravilo Lantus enkrat na dan, morajo za zmanjšanje nevarnosti nočne in zgodnje jutranje hipoglikemije dnevni odmerek bazalnega insulina v prvih tednih zdravljenja z zdravilom Lantus zmanjšati za 20 do 30%.
As with other insulin analogues, patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Lantus.
Tako kot pri drugih insulinskih analogih se lahko tudi po prehodu na zdravilo Lantus odziv na insulin izboljša bolnikom, ki zaradi protiteles proti humanemu insulinu potrebujejo velike odmerke insulina.
With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dosage regimen may become necessary.
Zaradi boljše urejenosti presnove in večje občutljivosti za insulin utegne biti potrebna nadaljnja prilagoditev odmerjanja.